Jun 10, 2020 by Paul BienstockHere's Why The Clouds Have Lifted For Quest DiagnosticsA quicker than expected recovery in routine testing and expansion in COVID-19 testing is driving better anticipated projected earnings for the second quarter.
May 6, 2020 by Paul BienstockWill Walgreens Investors Be Rewarded For Patience?The eventual stabilization in the business, a high dividend yield, and strong financial resources more than offset the near-term impact of COVID-19 on this pharmacy business.
Apr 9, 2020 by Paul BienstockHere's Why Regeneron’s Stock Is Worth More Than Its Coronavirus WorkThe company should benefit from continued growth in its core business of treating patients with eye disease, eczema, asthma, and cancer.
Apr 1, 2020 by Paul BienstockHere's Why Sanofi Is An Underappreciated Coronavirus StockThe pharma company is making progress on its portfolio of coronavirus therapies and the execution of its new growth strategy.
Mar 27, 2020 by Paul BienstockFor Gilead, Its Coronavirus Treatment Candidate Is Icing on the CakeThere are three good reasons to own Gilead aside from Remdesivir.
Feb 15, 2020 by Paul Bienstock3 High-Yielding U.S. Pharmaceutical Companies to ConsiderThese businesses have the winning trifecta: a stable dividend, ongoing earnings growth, and attractive valuation.
